Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Sponsor
Zhengzhou University
Study ID
NCT06956092
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • B Cell Lymphoma (BCL)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Glofitamab treatment — BIOLOGICAL
    eceive Glofitamab treatment as per the instructions in the package insert.

Study Details

The goal of this clinical trial is to learn if Glofitamab works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of Glofitamab treatment. The main questions it aims to answer are: * Does Glofitamab treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving Glofitamab treatment? In this investigator-initiated, single-arm clinical trial, participants will: * Receive Glofitamab treatment as per the instructions in the package insert. * Visit the clinic as instructed for checkups and tests.

Key Dates

Start date
May 30, 2025
Status verified
Apr 2025
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Glofitamab treatment

Primary Outcome Measure

two year PFS [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]

Central Contacts